Aarti Drugs

Aarti Drugs, an Indian pharmaceutical preparation manufacturer, has reported Scope 1 and 2 emissions for recent years. In 2023, their combined Scope 1 and 2 emissions were approximately 133,106,000 kg CO2e, consisting of 56,820,000 kg CO2e for Scope 1 and 76,414,000 kg CO2e for Scope 2 (location-based). Prior to this, in 2022, their Scope 1 emissions were approximately 56,820,000 kg CO2e, and their Scope 2 emissions were approximately 76,414,000 kg CO2e, making a total of approximately 133,234,000 kg CO2e.

For 2024, Aarti Drugs reported Scope 1 and 2 emissions totalling approximately 133,108,000 kg CO2e, with Scope 1 emissions around 54,888,000 kg CO2e and Scope 2 emissions around 78,220,000 kg CO2e. In 2025, their Scope 1 and 2 emissions were approximately 64,666,000 kg CO2e.

Aarti Drugs has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 50% by 2030, using 2020 as a baseline year. This target applies to all company sites. The company is actively reporting its emissions and has indicated that Scope 3 emissions, specifically purchased goods and services, are a missing data point.